← All trials
NCT03184402
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 24, 2017
- Primary completion
- Jul 31, 2017
- Completion date
- Jul 31, 2017
- First posted
- Jun 12, 2017
- Last posted
- Jun 26, 2019
- Enrollment
- 124
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Daewoong Pharmaceutical Co. LTD.Lead sponsor
- Seoul National UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.